Table 3: The occurrence of adverse cardiovascular events in 4-month and 4-year follow-ups of patients treated with PCI in the acute phase of myocardial infarction with persistent ST segment elevation depending on HbA1c level.
|
HbA1c level |
<6,5% |
vs |
≥6,5% |
|
<6,5% |
|
≥6,5% |
|
|
MACE |
after 4 months |
p value |
after 4 years |
p value |
||||
|
In Total |
8 (11.3%) |
vs |
4 (19.0%) |
0.690 |
23 (32.4%) |
vs |
11 (52.4%) |
0.387 |
|
Death |
1 (1.4%) |
vs |
1 (4.8%) |
|
3 (4.2%) |
vs |
3 (14.3%) |
|
|
Including cardiac |
1 (1,4%) |
vs |
0 |
|
1 (1.4%) |
vs |
2 (9.5%) |
|
|
Myocardial infarction |
1 (1,4%) |
vs |
1 (4.8%) |
|
7 (9.9%) |
vs |
4 (19.0%) |
|
|
PCI/CABG |
3 (4.2%) |
vs |
2 (9.5%) |
|
9 (12.7%) |
vs |
4 (19.0%) |
|
|
Hospitalisation due to CHF |
1 (1.4%) |
vs |
2 (9.5%) |
|
3 (4.2%) |
vs |
0 |
|
|
Stroke |
|
0 |
|
|
1 (1.4%) |
vs |
0 |
|